Framework can improve Alzheimer’s treatment efficacy by tracking anti-Aβ therapy response

In the last few years, progress has been made in the fight against Alzheimer’s disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These monoclonal anti-Aβs are proteins made in a laboratory to stimulate the immune system to slow the progression of the disease by targeting amyloid plaques in the brain that are characteristic of Alzheimer’s.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup